312 results on '"Khushman, Moh'd"'
Search Results
2. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
3. Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study
4. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
5. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma
6. Pain among older adults with gastrointestinal malignancies- results from the cancer and aging resilience evaluation (CARE) Registry
7. Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.
8. Detection of mitochondrial DNA mutations in circulating mitochondria-originated extracellular vesicles for potential diagnostic applications in pancreatic adenocarcinoma
9. Allele-specific KRAS mutations as prognostic biomarkers in mucinous adenocarcinoma of the appendix and colorectal cancer.
10. Neurological complications of GI cancers
11. Contributors
12. The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens
13. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
14. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer
15. The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival
16. Molecular profile of BRCA-mutated biliary tract cancers
17. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients
18. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis
19. Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC.
20. Genomic analysis of oesophageal carcinoma (EC) to identify recurrent mutations in histone methyltransferases as a distinctive subset.
21. Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.
22. Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.
23. APC as a high-utility mutational biomarker that may identify subpopulations of patients with mutant RAS/BRAF and right-sided colorectal cancer (CRC) who derive benefit from EGFR inhibitors (EGFRi).
24. Genomics and transcriptomics of pancreatic adenosquamous carcinoma.
25. Real-world testing, treatment patterns, and outcomes following liquid biopsy in advanced cholangiocarcinoma.
26. Abstract A006: Differential gene expression to delineate racial disparities in the molecular landscape of pancreatic ductal adenocarcinoma
27. Advances in Immunotherapy for Transplant Oncology.
28. 524 The association between mesothelial membranes metastasis and response to immune checkpoint inhibitors in solid tumors
29. MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin
30. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications
31. High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
32. Supplementary Figure 6 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
33. Supplementary Figure 7 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
34. Supplementary Figure 1 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
35. Supplementary Figure 5 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
36. Supplementary Figure 4 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
37. Supplementary Figure 8 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
38. Supplementary Data from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
39. Supplementary Figure 3 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
40. Supplementary Figure 2 from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
41. BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
42. Data from BZW2 Inhibition Reduces Colorectal Cancer Growth and Metastasis
43. Abstract 1003: The prognostic significance of prolyl 4-hydroxylase subunit alpha 1 and the therapeutic efficacy of diethyl-pythiDC, its small molecule inhibitor, in pancreatic ductal adenocarcinoma
44. Abstract 1297: BZW2 a potential target to inhibit colorectal cancer growth and metastasis
45. Figure S5 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
46. Supplementary Methods from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
47. Data from Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
48. Supplementary Table from Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
49. Supplementary Figure from Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
50. Supplementary Tables from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.